[1] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018. 68(6): 394-424.
[2] Pichler M, Hutterer GC, Chromecki TF, et al. Renal cell carcinoma stage migration in a single European centre over 25 years: effects on 5- and 10-year metastasis-free survival. International Urology & Nephrology. 2012. 44(4): 997-1004.
[3] Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part B: Prostate and Bladder Tumours. 2004. IARC Press.
[4] Steffens S, Janssen M, Roos FC, et al. Incidence and long-term prognosis of papillary compared to clear cell renal cell carcinoma – A multicentre study. Eur J Cancer. 2012. 48(15): 2347-2352.
[5] Gores GJ. Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res. 2000. 60(1): 184-190.
[6] Hainaut P, Plymoth A. Targeting the hallmarks of cancer: towards a rational approach to next-generation cancer therapy. Curr Opin Oncol. 2013. 25(1): 50.
[7] Grebien F, Hantschel O, Wojcik J, et al. & Weinberg, Robert A. Hallmarks of Cancer: The Next Generation. 2011 .
[8] Szkandera J, Stotz M, Absenger G, et al. Validation of C-reactive protein levels as a prognostic indicator for survival in a large cohort of pancreatic cancer patients. Br J Cancer. 2014. 110(1): 183-188.
[9] Kazuya Nakagawa MD, Kuniya Tanaka MD, PhD…. The Modified Glasgow Prognostic Score as a Predictor of Survival After Hepatectomy for Colorectal Liver Metastases. Ann Surg Oncol. 2014. 21(5): 1711-1718.
[10] Cho HB, Hur HW, Sang WK, et al. Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immunother. 2009. 58(1): 15-23.
[11] Aliustaoglu M, Bilici A, Ustaalioglu BB, et al. The effect of peripheral blood values on prognosis of patients with locally advanced gastric cancer before treatment. Med Oncol. 2010. 27(4): 1060-5.
[12] Templeton AJ, Ace O, Mcnamara MG, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. Breast Cancer Res. 2017. 19(1): 2.
[13] Viers BR, Houston Thompson R, Boorjian SA, Lohse CM, Leibovich BC, Tollefson MK. Preoperative neutrophil-lymphocyte ratio predicts death among patients with localized clear cell renal carcinoma undergoing nephrectomy. Urol Oncol. 2014. 32(8): 1277-84.
[14] Huang J, Dahl DM, Dong L, et al. Preoperative Neutrophil-to-Lymphocyte Ratio and Neutrophilia Are Independent Predictors of Recurrence in Patients with Localized Papillary Renal Cell Carcinoma. Biomed Res Int. 2015. 2015: 891045.
[15] Wen RM, Zhang YJ, Ma S, Xu YL, Zheng JN. Preoperative Neutrophil to Lymphocyte Ratio as a Prognostic Factor in Patients with Non-metastatic Renal Cell Carcinoma. Asian Pacific Journal of Cancer Prevention Apjcp. 2015. 16(9): 3703-3708.
[16] Cindolo L, Patard J, Chiodini P, et al. Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy: a multicenter European study. Cancer. 2010. 104(7).
[17] Multi-Institutional Validation of a New Renal Cancer-Specific Survival Nomogram. J Clin Oncol. 2007. 25(11): 1316-1322.
[18] Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol. 2002. 168(6): 2395-400.
[19] Viers BR, Boorjian SA, Frank I, et al. Pretreatment Neutrophil-to-Lymphocyte Ratio Is Associated with Advanced Pathologic Tumor Stage and Increased Cancer-specific Mortality Among Patients with Urothelial Carcinoma of the Bladder Undergoing Radical Cystectomy. Eur Urol. 2014. 66(6): 1157-1164.
[20] Huang J, Dahl DM, Liang D, et al. Preoperative Neutrophil-to-Lymphocyte Ratio and Neutrophilia Are Independent Predictors of Recurrence in Patients with Localized Papillary Renal Cell Carcinoma. Biomed Res Int. 2015. 2015: 1-9.
[21] Byun SS, Hwang EC, Kang SH, et al. Prognostic Significance of Preoperative Neutrophil-to-Lymphocyte Ratio in Nonmetastatic Renal Cell Carcinoma: A Large, Multicenter Cohort Analysis. Biomed Res Int. 2016. 2016: 5634148.
[22] Oh BS, Jang JW, Kwon JH, Chan RY, Lee S. Prognostic value of C-reactive protein and neutrophil-to-lymphocyte ratio in patients with hepatocellular carcinoma. BMC Cancer. 2013. 13(1): 78-78.
[23] Ingrid M, Markus M, Pascale K, Maria HG. Polymorphonuclear neutrophils and T lymphocytes: strange bedfellows or brothers in arms. Trends Immunol. 2009. 30(11).
[24] Hsu JT, Liao CK, Le PH, et al. Prognostic Value of the Preoperative Neutrophil to Lymphocyte Ratio in Resectable Gastric Cancer. Medicine (Abingdon). 2015. 94(39): e1589.
[25] Gu XB, Tian T, Tian XJ, Zhang XJ. Prognostic significance of neutrophil-to-lymphocyte ratio in non-small cell lung cancer: a meta-analysis. Sci Rep. 2015. 5: 12493.
[26] Soerensen AV, Donskov F, Hermann GG, et al. Improved overall survival after implementation of targeted therapy for patients with metastatic renal cell carcinoma: results from the Danish Renal Cancer Group (DARENCA) study-2. Eur J Cancer. 2014. 50(3): 553-62.
[27] Branche E, Tang WW, Viramontes KM, et al. Synergism between the tyrosine kinase inhibitor sunitinib and Anti-TNF antibody protects against lethal dengue infection. Antiviral Res. 2018. 158: 1-7.
[28] Zajkowska M, Ławicki S, Głażewska E, Będkowska G, Szmitkowski M. Plasma levels and diagnostic utility of VEGF, MMP-9, and TIMP-1 in the diagnosis of patients with breast cancer. Oncotargets & Therapy. 2016. 9.
[29] Patel A, Ravaud A, Motzer RJ, Pantuck AJ, George DJ. Neutrophil-to-lymphocyte ratio as a potential prognostic factor of disease-free survival in high-risk renal cell carcinoma: Analysis of the S-TRAC trial. J Clin Oncol. 2018. 36(15_suppl): 4562-4562.
[30] Lalani AA, Xie W, Martini DJ, et al. Change in Neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma. J Immunother Cancer. 2018. 6(1): 5.